Anthrax/Smallpox Scanners to be Showcased; Meditech Pharmaceuticals and Elan Bio to Demonstrate Scanner at BIO 2003.

Business Editors/Health/Medical Writers

BIO 2003 Annual Convention

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--May 8, 2003

Meditech Pharmaceuticals Inc. (OTCBB:MDCH) announced today that Elan Group Limited, Meditech's joint venture partner, and Meditech will be showcasing the joint venture's biohazard, chemical anti-terrorism solution on the world stage at BIO 2003. The company's non-invasive spectrometric scanning technology immediately detects the presence of dangerous poisons and pathogens including anthrax and can be inserted into mailroom conveyor belts, cradled in the hand of the user in a wand the size of a mobile phone or placed into a water supply.

Hosted by the Biotechnology Industry Organization in Washington from June 22 to 25, BIO 2003 is a convention attracting global companies seeking partnerships and networking opportunities. The Elan/Meditech joint venture is pursuing equity and potential strategic alliances and will be educating participants on its unique peaceful solution to bio-terrorism.

Having produced a bench-top prototype that successfully identifies the bacillus anthrasis genus with 100 percent validation through paper envelopes, Elan is confident its product will generate excitement.

"Instant, non-invasive detection is one of the fastest growing markets across multiple industries," said Colin Salmond, managing director, Elan Group Limited. "Elan has developed its spectrometric scanner to be suitable to a wide range of applications."

Elan's U.S. joint venture partner Meditech Pharmaceuticals Inc. will join the Australian firm at BIO 2003. Meditech is a drug development company focused on the development of human, veterinary and agricultural antimicrobial agents. Meditech was founded in 1982 as Medical Technology Corp. of America and went public via an IPO in 1983. It is intended that Elan and Meditech will jointly own the new company created from the JV.

"The new company intends to focus on commercializing and marketing the technologies of both companies in the U.S. and international markets," said Gerald N. Kern, CEO of Meditech Pharmaceuticals Inc. "Our initial research has been completed. We now have working prototype detection and prevention capabilities for aflatoxins and various other pathogens and poisons."

Elan Group's adaptable scanning equipment is capable of detecting and discriminating between strains within species, will maximize safety and minimize staff disruption, and eliminate the expense of hoaxes.

Elan has secured testing agreements for its detection technology with Australia Post, Air Services Australia and the Defence Science Technology Organization (Australia).

This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially. For a discussion of other risks that could cause actual results or events to differ materially from such forward-looking statements, see the discussion of ("Risks That Could Affect Our Financial Condition and Results of Operations") in Meditech's 10-KSB filing with the SEC for the year ended May 31, 2002. Meditech undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.